Ultragenyx

After Heron Therapeutics Inc (NASDAQ: HRTX), Bristol-Myers Squibb Co (NYSE: BMY) and Dynavax Technologies Corporation (NASDAQ: DVAX) found favor with the FDA, it's Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)'s turn, as the rare disease therapy company seeks FDA approval for its...

Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), a clinical-stage bio-pharmaceutical company, were trading higher by more than 7 percent Wednesday in reaction to an encouraging update regarding its Burosumab therapy which is used by patients with X-linked hypophosphatemia (XLH) in a Phase 3...